Last reviewed · How we verify

NCT04877548: P2F-GR

Powdered Fermented Fruits for Glycemia Reduction

Status unknown NA Last updated 20 September 2021
What this trial tests

NA trial testing Fermented orange flour in Cardiometabolic Risk Factors in 20 participants. Status unknown.

Timeline
7 September 2021
Primary endpoint
1 August 2022
1 August 2022

Quick facts

Lead sponsorHospices Civils de Lyon
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposebasic science
Enrollment20
Start date7 September 2021
Primary completion1 August 2022
Estimated completion1 August 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

Adults 25 to 65, any sex, with Cardiometabolic Risk Factors or Obesity, Abdominal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to evaluate the effects of an acute intake of two fermented fruits flours as part of a standardized breakfast, in comparison with the acute intake of a standardized breakfast without fermented fruits flour but with the same amount of available carbohydrates, on postprandial glycaemic response and overall metabolism in subjects at cardiometabolic risk. The metabolic parameters will be assessed in fasting and in postprandial period after the consumption of the standardized breakfast.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cardiometabolic Risk Factors

Currently open trials in the same condition.

Other Hospices Civils de Lyon trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04877548.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing